These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 2508531)

  • 1. Tissue plasminogen activator and cholesterol crystal embolization.
    Bhardwaj M; Goldweit R; Erlebacher J; Kashani M; Levin D; Leber G
    Ann Intern Med; 1989 Oct; 111(8):687-8. PubMed ID: 2508531
    [No Abstract]   [Full Text] [Related]  

  • 2. Cholesterol embolization after treatment with tissue plasminogen activator.
    Shapiro LS
    N Engl J Med; 1989 Nov; 321(18):1270. PubMed ID: 2507919
    [No Abstract]   [Full Text] [Related]  

  • 3. Cholesterol crystal embolization-associated renal failure after therapy with recombinant tissue-type plasminogen activator.
    Gupta BK; Spinowitz BS; Charytan C; Wahl SJ
    Am J Kidney Dis; 1993 Jun; 21(6):659-62. PubMed ID: 8503421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasminogen activator and cerebral infarction.
    Cranston RE; Wolfson MA; Buchsbaum HW; Feinberg WM; Barreuther A
    Ann Intern Med; 1988 May; 108(5):766. PubMed ID: 3128954
    [No Abstract]   [Full Text] [Related]  

  • 5. Cholesterol embolization syndrome following thrombolytic therapy with streptokinase and tissue plasminogen activator.
    Ben-Chitrit S; Korzets Z; Hershkovitz R; Bernheim J; Schneider M; Bernheim J
    Nephrol Dial Transplant; 1994; 9(4):428-30. PubMed ID: 8084460
    [No Abstract]   [Full Text] [Related]  

  • 6. Angioedema during therapy with recombinant tissue plasminogen activator.
    Francis CW; Brenner B; Leddy JP; Marder VJ
    Br J Haematol; 1991 Apr; 77(4):562-3. PubMed ID: 1902745
    [No Abstract]   [Full Text] [Related]  

  • 7. Oropharyngeal angioneurotic edema due to recombinant tissue plasminogen activator following massive pulmonary thromboembolism.
    Ekmekçi P; Bengisun ZK; Kazbek BK; Akmansu H; Beriat GK; Süer AH
    Int Immunopharmacol; 2011 Sep; 11(9):1384-5. PubMed ID: 21570492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute pulmonary embolism treated with tissue plasminogen activator.
    Goldhaber SZ; Vaughan DE; Markis JE; Selwyn AP; Meyerovitz MF; Loscalzo J; Kim DS; Kessler CM; Dawley DL; Sharma GV
    Lancet; 1986 Oct; 2(8512):886-9. PubMed ID: 2876327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholesterol emboli syndrome occurring after administration of tissue plasminogen activator.
    Baldwin SH; Musa J
    J Miss State Med Assoc; 2002 Apr; 43(4):108. PubMed ID: 11989190
    [No Abstract]   [Full Text] [Related]  

  • 10. Tissue plasminogen activator and intracranial hemorrhage.
    Becker RC; Gore JM
    Ann Intern Med; 1990 Apr; 112(8):630. PubMed ID: 2109564
    [No Abstract]   [Full Text] [Related]  

  • 11. Purple toes syndrome following stroke thrombolysis and warfarin therapy.
    Mooney T; Joseph P
    Intern Med J; 2014 Jan; 44(1):107-8. PubMed ID: 24450530
    [No Abstract]   [Full Text] [Related]  

  • 12. [The thrombolytic treatment of acute and subacute recurrent pulmonary embolism with recombinant tissue plasminogen activator].
    Tiede N; Kasper W; Geibel A; Bassenge D; Langenstein B; Meinertz T; Just H
    Dtsch Med Wochenschr; 1990 Nov; 115(45):1699-704. PubMed ID: 2121453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant tissue plasminogen activator (rt-PA).
    Epstein C
    Aust Nurses J; 1992 Mar; 21(8):29-30. PubMed ID: 1605783
    [No Abstract]   [Full Text] [Related]  

  • 14. [Can systemic changes in the blood coagulation system be detected in low-dose local thrombolysis with r-tPA?].
    Weichenhain B; Stiegler H; Spengel F; Standl E; Woitinas F; Roth R; Schulz K; Mehnert H
    Vasa Suppl; 1991; 32():314-7. PubMed ID: 1771523
    [No Abstract]   [Full Text] [Related]  

  • 15. Contrast extravasation from a Pulse-Tec graft: a complication of high-dose recombinant tissue-type plasminogen activator therapy.
    Buckenham TM; Taylor RS; Reiff D; Page JE
    Br J Radiol; 1992 Jun; 65(774):545-7. PubMed ID: 1628190
    [No Abstract]   [Full Text] [Related]  

  • 16. [Cholesterol crystal embolisms due to systemic thrombolysis of an acute myocardial infarct].
    Diethelm A; Vorburger C; Anabitarte M; Haag E
    Schweiz Med Wochenschr; 1994 Aug; 124(33):1437-41. PubMed ID: 7939511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atheroembolic disease following administration of tissue plasminogen activator (TPA).
    Aggarwal K; Tjahja IE
    Clin Cardiol; 1996 Nov; 19(11):906-8. PubMed ID: 8914787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Life-threatening anaphylactoid shock caused by recombinant tissue plasminogen activator.
    Wang CT; Lin FC; Khor GT; Chen CH; Huang P
    Am J Emerg Med; 2012 Jan; 30(1):253.e1-2. PubMed ID: 21109385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effectiveness and tolerance of rt-Pa for local lytic therapy of 53 embolic and thrombotic occlusions of the lower extremity].
    Spengel FA; Küffer G; Hufen V; Stiegler H
    Vasa Suppl; 1991; 33():127. PubMed ID: 1788642
    [No Abstract]   [Full Text] [Related]  

  • 20. [Acute orolingual angioedema associated to recombinant human tissue plasminogen activator treatment].
    Rivera-Rubiales G; Garcia-Delgado H; Egea-Guerrero JJ
    Med Intensiva; 2015 Dec; 39(9):585-6. PubMed ID: 26391737
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.